Literature DB >> 21669377

The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults.

Amanda R Patrick1, William H Shrank, Robert J Glynn, Daniel H Solomon, Colin R Dormuth, Jerry Avorn, Suzanne M Cadarette, Helen Mogun, M Alan Brookhart.   

Abstract

OBJECTIVE: To explore the "healthy user" and "healthy adherer" effects-hypothetical sources of bias thought to arise when patients who initiate and adhere to preventive therapies are more likely to engage in healthy behaviors than are other subjects.
METHODS: The authors examined the association between statin initiation and adherence, and the subsequent use of preventive health services and incidence of clinical outcomes unlikely to be associated with the need for, or use of, a statin among older enrollees in two state-sponsored drug benefit programs.
RESULTS: After adjustment for demographic and clinical covariates, patients who initiated statin use were more likely to receive recommended preventive services than noninitiators matched on age, sex, and state (hazard ratio [HR]: 1.10, 1.06-1.14 for males, HR: 1.09, 1.07-1.11 for females) and appeared to have a lower risk of a range of adverse outcomes (HR: 0.87, 0.85-0.89) thought to be unrelated to statin use. Adherence to a statin regimen was also associated with increased rates of preventive service use and a decreased rate of adverse clinical outcomes (HR: 0.93, 0.88-0.99).
CONCLUSIONS: These results suggest that patients initiating and adhering to chronic preventive drug therapies are more likely to engage in other health-promoting behaviors. Failure to account for this relationship may introduce bias in any epidemiologic study evaluating the effect of a preventive therapy on clinical outcomes.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669377      PMCID: PMC5059150          DOI: 10.1016/j.jval.2010.10.033

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  31 in total

Review 1.  A meta-analysis of the association between adherence to drug therapy and mortality.

Authors:  Scot H Simpson; Dean T Eurich; Sumit R Majumdar; Rajdeep S Padwal; Ross T Tsuyuki; Janice Varney; Jeffrey A Johnson
Journal:  BMJ       Date:  2006-06-21

2.  Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results.

Authors:  Sebastian Schneeweiss; Amanda R Patrick; Til Stürmer; M Alan Brookhart; Jerry Avorn; Malcolm Maclure; Kenneth J Rothman; Robert J Glynn
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

3.  Hormone replacement therapy, heart disease, and other considerations.

Authors:  E Barrett-Connor; D Grady
Journal:  Annu Rev Public Health       Date:  1998       Impact factor: 21.981

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Selective prescribing led to overestimation of the benefits of lipid-lowering drugs.

Authors:  Robert J Glynn; Sebastian Schneeweiss; Philip S Wang; Raia Levin; Jerry Avorn
Journal:  J Clin Epidemiol       Date:  2006-05-26       Impact factor: 6.437

6.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

Authors:  Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

Review 7.  Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies.

Authors:  E Garbe; S Suissa
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

8.  Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.

Authors:  Aukje K Mantel-Teeuwisse; Olaf H Klungel; Toine C G Egberts; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect.

Authors:  M Alan Brookhart; Amanda R Patrick; Colin Dormuth; Jerry Avorn; William Shrank; Suzanne M Cadarette; Daniel H Solomon
Journal:  Am J Epidemiol       Date:  2007-05-15       Impact factor: 4.897

10.  Debate: The potential role of estrogen in the prevention of heart disease in women after menopause.

Authors:  Jacques E Rossouw
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000
View more
  24 in total

1.  Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.

Authors:  Jeffrey R Curtis; Huifeng Yun; Jeff L Lange; Robert Matthews; Pradeep Sharma; Kenneth G Saag; Elizabeth Delzell
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

2.  Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies.

Authors:  Stacie B Dusetzina; M Alan Brookhart; Matthew L Maciejewski
Journal:  Health Serv Res       Date:  2015-01-19       Impact factor: 3.402

3.  Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes.

Authors:  Sylvie Perreault; Amy Y X Yu; Robert Côté; Alice Dragomir; Brian White-Guay; Stéphanie Dumas
Journal:  Neurology       Date:  2012-10-31       Impact factor: 9.910

4.  Effect of statin use on acute kidney injury risk following coronary artery bypass grafting.

Authors:  J Bradley Layton; Abhijit V Kshirsagar; Ross J Simpson; Virginia Pate; Michele Jonsson Funk; Til Stürmer; M Alan Brookhart
Journal:  Am J Cardiol       Date:  2012-12-28       Impact factor: 2.778

5.  Evidence for Detection Bias by Medication Use in a Cohort Study of Breast Cancer Survivors.

Authors:  Heidi S Wirtz; Gregory S Calip; Diana S M Buist; Julie R Gralow; William E Barlow; Shelly Gray; Denise M Boudreau
Journal:  Am J Epidemiol       Date:  2017-04-15       Impact factor: 4.897

6.  Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study.

Authors:  Candace H Feldman; Karen H Costenbader; Daniel H Solomon; S V Subramanian; Ichiro Kawachi
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07       Impact factor: 4.794

Review 7.  Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Abha Goyal Singh; Preet Paul Singh; Mohammad Hassan Murad; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

8.  Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations.

Authors:  Shirley V Wang; Joshua J Gagne; Robert J Glynn; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2013-05       Impact factor: 4.822

9.  Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation.

Authors:  Federico Rea; Giulia Calusi; Matteo Franchi; Davide Liborio Vetrano; Giuseppe Roberto; Stefano Bonassi; Ursula Kirchmayer; Alessandro Chinellato; Alessandra Bettiol; Janet Sultana; Alessandro Mugelli; Giovanni Corrao
Journal:  Drugs Aging       Date:  2018-12       Impact factor: 3.923

10.  Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities.

Authors:  Heli Halava; Maarit Jaana Korhonen; Risto Huupponen; Soko Setoguchi; Jaana Pentti; Mika Kivimäki; Jussi Vahtera
Journal:  CMAJ       Date:  2014-06-23       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.